ArticleEndocrine2025
Clinical and radiological insights into secondary hypophysitis: A single-center experience with a focus on tuberculosis.
Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSecondary hypophysitis (apart from immune checkpoint inhibitor [ICI] induced) is rare and is largely described in case series. We aim to describe the distinctive characteristics of the various etiologies of secondary hypophysitis from a single center.
methodsA retrospective record review of 44 patients with secondary hypophysitis (excluding ICI) presenting to our institute between January 2002 and January 2023 was performed. The data of primary hypophysitis managed medically (n = 39) was retrieved from a prior publication and compared with common etiologies of secondary hypophysitis.
resultsThe most common etiologies were histiocytic disorders - Langerhans cell histiocytosis (LCH) and Erdheim Chester disease (ECD) [n = 23] and tubercular hypophysitis (TH) [n = 10]. LCH/ECD were characterized by multisystem involvement, with arginine vasopressin deficiency (AVP-D) [22/23] being the predominant endocrine presentation. TH patients presented with mass effect (9/10), focal non-enhancing areas within an enhancing sellar/suprasellar mass on magnetic resonance imaging (MRI) (10/10), with evidence of tuberculosis elsewhere in 60%. Though caseating granulomas were universal on histopathology, bacteriological confirmation was negative in all pituitary specimens. When compared to primary hypophysitis, isolated infundibuloneurohypophysitis and AVP-D were more prevalent in LCH/ECD, while the presence of a sellar/suprasellar mass with focal non-enhancing areas was more frequent in TH. Furthermore, recovery of the hormonal axis upon follow-up was more common in primary hypophysitis.
conclusionSecondary hypophysitis in our cohort was predominantly histiocytic or tubercular in etiology, with LCH/ECD presenting largely with AVP-D and TH presenting with mass effects, focal non-enhancing areas, and paucibacillary disease.
Indexed as
Identifiers
40627285What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.